Sidebar: Cancer Resources The field of cancer research has been dramatically altered by advances in molecular biology. In some cases, investigators can tease out the precise molecular route by which cells turn cancerous and how those calls are affected by treatments. Researchers are working to understand the nuances of oncogenes, or cancer-causing genes. Others have located cancer susceptibility genes, providing hope for future screening methods and potential treatments. As scientists continue
Sidebar: Cancer Resources
 GROWING FIELD: Cancer genetics has "blossomed in the last few years," notes American Cancer Society’s Harmon Eyre. |
 PREVENTIVE EMPHASIS: Columbia’s Frederica Perera says identifying causal factors is a key to effective intervention. |
"We need more emphasis on preventing cancer by identifying causal factors early on to be able ...
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
